Management of Hyperphosphatemia

Initial Assessment and Risk Stratification

The National Kidney Foundation recommends immediately restricting dietary phosphorus to 800-1,000 mg/day and initiating phosphate binders when serum phosphorus exceeds 4.6 mg/dL in CKD stages 3-4 or 5.5 mg/dL in stage 5/dialysis patients 1, 2
Hyperphosphatemia in CKD develops when GFR declines to 20-30 mL/min/1.73 m² (Stage 4), though phosphate retention begins much earlier at Stage 2 1, 2
Serum phosphorus >6.5 mg/dL is associated with significantly increased all-cause and cardiovascular mortality 3
Vascular calcification risk increases dramatically when calcium-phosphorus product exceeds 55 mg²/dL² 3, 4

Limit phosphorus intake to 800-1,000 mg/day while maintaining adequate protein intake 1, 2, 4
Emphasize avoidance of processed foods containing phosphate additives, which have higher bioavailability than naturally occurring phosphates 4
Provide intensive dietary counseling with increased dietitian-to-patient ratio 1
Monitor serum phosphorus monthly following initiation of dietary restriction 1, 2

For patients with corrected serum calcium ≤10.2 mg/dL and no severe vascular calcification, the American College of Physicians recommends limiting total elemental calcium intake from all sources to <2,000 mg/day 3, 4
Use non-calcium-based binders (sevelamer or lanthanum carbonate) as first-line therapy for patients with corrected serum calcium >10.2 mg/dL, PTH <150 pg/mL, or severe vascular/soft-tissue calcifications 3, 4
Avoid aluminum-based binders for long-term management due to toxicity risk 4
Consider combination therapy with different phosphate binders if single agent is insufficient 4

Maintain serum phosphorus within these ranges: CKD Stages 3-4: 2.7-4.6 mg/dL (treat when >4.6 mg/dL) and CKD Stage 5/dialysis: 3.5-5.5 mg/dL (treat when >5.5 mg/dL) 1, 3, 4
Keep calcium-phosphorus product <55 mg²/dL² at all times 3, 4

Monitor serum phosphorus, calcium, and PTH levels at least every 3 months in ESRD patients 5
Base treatment decisions on trends of serial measurements, not single values 5, 4
Assess for signs of vascular calcification and cardiovascular disease progression 3
Monitor for hypercalcemia when using calcium-based binders or vitamin D analogs 5

If PTH remains elevated despite phosphate control, address vitamin D deficiency with supplementation 5
Reserve calcitriol or vitamin D analogs only for severe and progressive secondary hyperparathyroidism, starting with low doses while avoiding hypercalcemia 5
Consider parathyroidectomy for severe, refractory cases 5

Ensure efficient dialytic phosphate removal through adequate dialysis prescription 1
Consider intensified dialysis regimens (nocturnal or daily hemodialysis) for patients unable to achieve target phosphorus levels 1

Do not use calcium-based binders when calcium >10.2 mg/dL or severe calcifications present - this paradoxically worsens vascular calcification despite controlling phosphorus 3
Do not exceed 2,000 mg/day total elemental calcium from all sources - calcium loads >2.18 g/day are associated with progressive vascular calcification 3
Do not overly suppress PTH - normal or low PTH in ESRD indicates adynamic bone disease, which is also problematic 5
Do not treat normophosphatemia preventively with phosphate binders - this has not shown benefit and may cause harm 4
Do not focus solely on PTH without addressing hyperphosphatemia - this fails to prevent cardiovascular complications that drive mortality 3

For acute, severe hyperphosphatemia with symptomatic hypocalcemia, hemodialysis is the definitive treatment to rapidly lower phosphorus 3
Aluminum-based phosphate binders may be used for short-term therapy only while arranging dialysis 3